|
Session 132
Poster Abstracts
Antiretroviral Drug Toxicities and Other Systemic Complications of HIV Disease
Tuesday, 1:30 - 3:30 pm
Poster Hall |
769
 |
Early, Uninterrupted ART Is Associated with Improved Outcomes and Fewer Toxicities in the HIV Outpatient Study (HOPS)
Kenneth Lichtenstein*1, C Armon2, K Buchacz3, A Moorman3, K Wood2, J Brooks3, and HIV Outpatient Study
1Univ of Colorado Hlth Sci Ctr, Denver, US; 2Cerner Corp, Vienna, VA, US; and 3CDC, Atlanta, GA, US |
770
|
Exposure to ART and the Risk of Liver-related Death: Is there an Association? Results from the D:A:D Study
Rainer Weber*1, C Sabin2, N Friis-Mĝller3, A D'Arminio Monforte4, P Reiss5, W El-Sadr6, F Dabis7, M Law8, C Pradier9, S De Wit10, and on behalf of the D:A:D Study Group
1SHCS, Univ Hosp Zürich, Switzerland; 2Royal Free Ctr for HIV Med, Royal Free and Univ Coll, London, UK; 3Copenhagen HIV Prgm, Hvidovre, Denmark; 4ICONA, L Sacco Hosp, Univ of Milan, Italy; 5HIV Monitoring Fndn, Academic Med Ctr, Univ of Amsterdam, The Netherlands; 6CPCRA, Columbia Univ, Harlem Hosp, New York, NY, US; 7Bordeaux Univ Hosp, INSERM U593, France; 8Australian HIV Observational Database, Natl Ctr in HIV Epidemiology and Clin Res, Sydney; 9Nice Cohort, CHU Nice Hosp de l'Archet, France; and 10Ctr Hosp Univ St Pierre, Brussels, Belgium |
771
|
Impaired Renal Function of Patients Initiating HAART in 2 Developing Countries
David Olson*1, E Thomas2, M Allheimen3, S Balkan4, E Szumilin4, and P Humblet5
1Doctors without Borders, New York, NY, US; 2MSF-France, Arua, Uganda; 3MSF-France, Guatemala City, Guatemala; 4MSF-France, Paris; and 5MSF-Belgium, Brussels |
772
|
High Risk of Unrecognized Adrenal Suppression and Symptoms of Steroid Excess in HIV+ Clinic Patients Exposed to Ritonavir and Topical Fluticasone: Results of a Case-control Study
Mark Hull*1,2, E Phillips1,3, M Harris2,3, G Bondy4, P Leong4, J Toy4, R Hogg1,3, J Singer1,2, and J Montaner1,2,3
1Univ of British Columbia, Vancouver, Canada; 2Canadian HIV Trials Network, Vancouver, Canada; 3BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; and 4St. Paul's Hosp, Vancouver, BC, Canada |
| 773 |
Long-term Neuropsychological Effects of Efavirenz-based Treatment
David Clifford*1, S Evans2, Y Yang2, R Gulick3, and A5097S Team
1Washington Univ, St Louis, MO, US; 2Harvard Sch of Publ Hlth, Cambridge, MA, US; and 3Weill Med Coll of Cornell Univ, New York, NY, US |
| 774 |
HIV Protease Inhibitors and the Hepatic Metabolome
Oliver Flint*1, C Elosua1, C Hamilton2, R Parker1, and M Noor1
1Bristol-Myers Squibb, Princeton, NJ, US and 2Metabolon, Research Triangle Park, NC, US |
775
|
Prevalence and Risk Factors of Hypogonadism among HIV-infected Men
Nancy Crum-Cianflone*1,2, M Bavaro2, B Hale2, A Truett2, T Powell1, S Medina1, C Brandt1, B Pope1, K Furtek1, M Wallace2, and on behalf of the TriSvc AIDS Clin Consortium
1TriSvc AIDS Clin Consortium, Rockville, MD, US and 2Naval Med Ctr, San Diego, CA, US |
776
|
Erectile Dysfunction among HIV-infected Men
Nancy Crum-Cianflone*1,2, B Hale2, M Bavaro2, A Truett2, S Medina1, C Brandt1, B Pope1, K Furtek1, P Olson1, M Wallace2, and the TriSvc AIDS Clin Consortium
1TriSvc AIDS Clin Consortium, Lackland Air Force Base, TX, US and 2Naval Med Ctr, San Diego, CA, US |
|
